New Drug Pricing Law Puts Cancer Drugs in the Spotlight

August 24, 2022

(Axios) – The drug industry argues that the new law will keep oncology treatments from reaching some patients who need them. But experts say the current system lets companies profit from developing drugs that yield only incremental advances — and that cancer drugs will still be valuable enough for companies to pursue. The big picture: The dispute over how Medicare drug price negotiations affect cancer care is a microcosm of a larger debate, in which the pharmaceutical industry argues that price controls will reduce their incentive to bring new drugs to market. (Read More)